FY2024 Earnings Estimate for ITCI Issued By Leerink Partnrs

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Stock analysts at Leerink Partnrs increased their FY2024 EPS estimates for Intra-Cellular Therapies in a research report issued on Wednesday, October 30th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn ($0.35) per share for the year, up from their previous estimate of ($0.50). The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.63) per share. Leerink Partnrs also issued estimates for Intra-Cellular Therapies’ Q4 2024 earnings at $0.22 EPS and FY2026 earnings at $2.85 EPS.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. Intra-Cellular Therapies’s revenue was up 39.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.25) EPS.

Other analysts have also issued reports about the stock. The Goldman Sachs Group cut their target price on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. UBS Group decreased their price objective on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a report on Monday, September 16th. Royal Bank of Canada boosted their target price on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Finally, JPMorgan Chase & Co. raised their price objective on Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $97.23.

Intra-Cellular Therapies Stock Down 0.4 %

Shares of Intra-Cellular Therapies stock opened at $86.17 on Monday. The business’s fifty day simple moving average is $75.41 and its 200-day simple moving average is $73.31. Intra-Cellular Therapies has a 52 week low of $52.88 and a 52 week high of $88.00. The firm has a market cap of $9.14 billion, a PE ratio of -99.04 and a beta of 0.97.

Institutional Investors Weigh In On Intra-Cellular Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new position in Intra-Cellular Therapies in the first quarter valued at approximately $32,000. Fidelis Capital Partners LLC purchased a new position in shares of Intra-Cellular Therapies in the 1st quarter valued at $53,000. Summit Securities Group LLC acquired a new position in shares of Intra-Cellular Therapies during the 2nd quarter valued at $56,000. Capital Performance Advisors LLP purchased a new stake in Intra-Cellular Therapies during the 3rd quarter worth $74,000. Finally, CWM LLC increased its holdings in Intra-Cellular Therapies by 83.9% in the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 626 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 34,396 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Mark Neumann sold 18,714 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at $2,229,876. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sharon Mates sold 34,396 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $77,962,764.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 175,316 shares of company stock valued at $13,037,345. 2.60% of the stock is owned by insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.